367 related articles for article (PubMed ID: 19749791)
21. Wild-type p53 in cancer cells: when a guardian turns into a blackguard.
Kim E; Giese A; Deppert W
Biochem Pharmacol; 2009 Jan; 77(1):11-20. PubMed ID: 18812169
[TBL] [Abstract][Full Text] [Related]
22. The effects of a mutant p53 protein on the proliferation and differentiation of PC12 rat phaeochromocytoma cells.
Fábián Z; Vecsernyés M; Pap M; Szeberényi J
J Cell Biochem; 2006 Dec; 99(5):1431-41. PubMed ID: 16817227
[TBL] [Abstract][Full Text] [Related]
23. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control.
Pollock R; Lang A; Ge T; Sun D; Tan M; Yu D
Clin Cancer Res; 1998 Aug; 4(8):1985-94. PubMed ID: 9717829
[TBL] [Abstract][Full Text] [Related]
24. Protein tyrosine phosphatase receptor type Z dephosphorylates TrkA receptors and attenuates NGF-dependent neurite outgrowth of PC12 cells.
Shintani T; Noda M
J Biochem; 2008 Aug; 144(2):259-66. PubMed ID: 18477627
[TBL] [Abstract][Full Text] [Related]
25. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact.
Girnita L; Girnita A; Brodin B; Xie Y; Nilsson G; Dricu A; Lundeberg J; Wejde J; Bartolazzi A; Wiman KG; Larsson O
Cancer Res; 2000 Sep; 60(18):5278-83. PubMed ID: 11016658
[TBL] [Abstract][Full Text] [Related]
26. TrkA overexpression enhances growth and metastasis of breast cancer cells.
Lagadec C; Meignan S; Adriaenssens E; Foveau B; Vanhecke E; Romon R; Toillon RA; Oxombre B; Hondermarck H; Le Bourhis X
Oncogene; 2009 May; 28(18):1960-70. PubMed ID: 19330021
[TBL] [Abstract][Full Text] [Related]
27. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53.
Angelo LS; Talpaz M; Kurzrock R
Cancer Res; 2002 Feb; 62(3):932-40. PubMed ID: 11830554
[TBL] [Abstract][Full Text] [Related]
28. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
29. [Effect of HSP90 function inhibited on the telomerase and P53 mutant in breast cancer cells].
Li X; Deng HY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 39(2):181-3. PubMed ID: 18630678
[TBL] [Abstract][Full Text] [Related]
30. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
Mizuarai S; Yamanaka K; Kotani H
Cancer Res; 2006 Jun; 66(12):6319-26. PubMed ID: 16778209
[TBL] [Abstract][Full Text] [Related]
31. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein.
Vinyals A; Peinado MA; Gonzalez-Garrigues M; Monzó M; Bonfil RD; Fabra A
Gene Ther; 1999 Jan; 6(1):22-33. PubMed ID: 10341872
[TBL] [Abstract][Full Text] [Related]
32. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
[TBL] [Abstract][Full Text] [Related]
33. Localization of NGF and TrkA at mitotic apparatus in human glioma cell line U251.
Zhang Z; Yang Y; Gong A; Wang C; Liang Y; Chen Y
Biochem Biophys Res Commun; 2005 Nov; 337(1):68-74. PubMed ID: 16181609
[TBL] [Abstract][Full Text] [Related]
34. Telomere erosion triggers growth arrest but not cell death in human cancer cells retaining wild-type p53: implications for antitelomerase therapy.
Preto A; Singhrao SK; Haughton MF; Kipling D; Wynford-Thomas D; Jones CJ
Oncogene; 2004 May; 23(23):4136-45. PubMed ID: 15064743
[TBL] [Abstract][Full Text] [Related]
35. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
36. Immortalization of human mammary epithelial cells transfected with mutant p53 (273his).
Gollahon LS; Shay JW
Oncogene; 1996 Feb; 12(4):715-25. PubMed ID: 8632893
[TBL] [Abstract][Full Text] [Related]
37. HER-2/neu raises SHP-2, stops IFN-gamma anti-proliferation in bladder cancer.
Su WP; Tu IH; Hu SW; Yeh HH; Shieh DB; Chen TY; Su WC
Biochem Biophys Res Commun; 2007 Apr; 356(1):181-6. PubMed ID: 17346677
[TBL] [Abstract][Full Text] [Related]
38. TrkA NGF receptor plays a role in the modulation of p75NTR expression.
Rankin SL; Guy CS; Mearow KM
Neurosci Lett; 2005 Aug; 383(3):305-10. PubMed ID: 15955426
[TBL] [Abstract][Full Text] [Related]
39. Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53.
Ueda K; Arakawa H; Nakamura Y
Oncogene; 2003 Aug; 22(36):5586-91. PubMed ID: 12944906
[TBL] [Abstract][Full Text] [Related]
40. A food-derived synergist of NGF signaling: identification of protein tyrosine phosphatase 1B as a key regulator of NGF receptor-initiated signal transduction.
Shibata T; Nakahara H; Kita N; Matsubara Y; Han C; Morimitsu Y; Iwamoto N; Kumagai Y; Nishida M; Kurose H; Aoki N; Ojika M; Uchida K
J Neurochem; 2008 Dec; 107(5):1248-60. PubMed ID: 18796006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
